Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Blood (2024) 144 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2024-209462

Published: 2024

Journal Articles

Integrating Genomics and Functional Phenotypes to Refine Risk Assessment in Acute Myeloid Leukemia across the Age Spectrum: Insights from Singapore

Prasad Iyer, Shaista Shabbir Jasdanwala, Xiao Xian Lin, Karanpreet Singh Bhatia, Germaine Shimin Liew, Si Ting Tai, Jameelah Sheik Mohamed, Wei-Ying Jen, Melissa Gaik-Ming Ooi, Allen Eng Juh Yeoh, Shruti Bhatt

Blood (2024) 144 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2024-212029

Published: 2024

Journal Articles

Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia

Naszrin Arani, Wei-Ying Jen, Alex Bataller, Alexandre Bazinet, Farhad Ravandi, Naval Daver, Koichi Takahashi, Sanam Loghavi, Hussein A. Abbas, Emmanuel Almanza, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Courtney D. DiNardo, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4293.

https://doi.org/10.1182/blood-2024-202577

Published: 2024

Journal Articles

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Emmanuel Almanza, Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero, Naveen Pemmaraju, Lucia Masarova, Sherry Pierce, Naval Daver, Alex Bataller, Guillermo Garcia-Manero, Amin M. Alousi, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2024-209558

Published: 2024

Journal Articles

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Caitlin R Rausch, Emmanuel Almanza-Huante, Wei-Ying Jen, Guillermo Montalban-Bravo, Farhad Ravandi, Kelly S. Chien, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Abhishek Maiti, Joseph E. Jabbour, Ghayas C. Issa, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2024-203831

Published: 2024

Journal Articles

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2024-212036

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Characteristics and Outcomes of Acute Myeloid Leukemia in Ethnically Diverse Asians in Singapore

Natasha Fay Anthony, Yen-Lin Chee, Pak Ling Lui, Esther Chan, Michelle Poon, Lip Kun Tan, Jameelah Binte Sekh Mohamed, Liang Piu Koh, Melissa G OOI, Wee-Joo Chng, Wei-Ying Jen

Blood (2024) 144 (Supplement 1): 7899.

https://doi.org/10.1182/blood-2024-198845

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blood (2024) 144 (Supplement 1): 841.

https://doi.org/10.1182/blood-2024-204042

Published: 2024

Journal Articles

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Eitan Kugler, Hagop M. Kantarjian, Alexandre Bazinet, Wei-Ying Jen, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Jayastu Senapati, Gautam Borthakur, Naveen Pemmaraju, Ghayas C. Issa, Alex Bataller, Patrick K. Reville, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2024-199903

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network

Wei-Ying Jen, Melissa Ooi, Sanjay De Mel, Cinnie Soekojo, Sung-Soo Yoon, Xinhua Li, Neha Awasthi, Sarah M Burkill, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 2009.

https://doi.org/10.1182/blood-2023-180017

Published: 2023

Journal Articles

Clinical Evaluation of a Functional Combinatorial Precision Medicine Platform to Predict Patient-Specific Treatment Outcomes in Acute Myeloid Leukemia

Edward Chow, Noor Rashidha Binte Meera Sahib, Masturah Rashid, Jhin Jieh Lim, Wei-Ying Jen, Melissa Ooi

Blood (2023) 142 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2023-186251

Published: 2023

Journal Articles

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2023-182997

Published: 2023

Journal Articles

Survival Outcomes, Efficacy and Tolerability of a Pediatric-Inspired Regimen (MASPORE) for Philadelphia-Negative Acute Lymphoblastic Leukemia in Young Adults at a Tertiary Hospital in Singapore

Victor Ling Wei Teik, Sai Lon Wann, Jing Yuan Tan, Jameelah Sheik Mohamed, Wei Ying Jen, Pak Ling Lui, Michelle Poon, Esther Hian Li Chan, Liang Piu Koh, Lip Kun Tan, Chin Hin Ng, Allen Eng Juh Yeoh, Melissa Ooi

Blood (2023) 142 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2023-189139

Published: 2023

Journal Articles

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Yang Song, Jin Seok Kim, CS Chim, Je-Jung Lee, Sung-Soo Yoon, Soo Chin Ng, Gin Gin Gan, Hiroshi Handa, Wei-Ying Jen, Xinhua Li, Yogesh Mahadev Pokharkar, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2023-184723

Published: 2023

Journal Articles

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Yesid Alvarado-Valero, Lucia Masarova, Mark Brandt, Debra Bull-Linderman, Naval Daver, Guillermo Montalban-Bravo, Alex Bataller, Guillermo Garcia-Manero, Ghayas C. Issa, Amin Alousi, Nicholas J. Short, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4273.

https://doi.org/10.1182/blood-2023-182969

Published: 2023

Journal Articles

Mitochondrial Functional Profiling Links Apoptotic Sensitivity to Treatment Outcomes Based on Age and Cell Lineage in Acute Leukemia

Prasad Ramanakrishnan Iyer, Shaista Shabbir Jasdanwala, Jameelah Binte Sekh Mohamed, Si Ting Tai, Wei-Ying Jen, Melissa Ooi, Allen Eng Juh Yeoh, Shruti Bhatt

Blood (2023) 142 (Supplement 1): 5966.

https://doi.org/10.1182/blood-2023-188541

Published: 2023

Journal Articles

Development of a Novel Artificial Intelligence Tool to Measure Psoas Volumes in Patients with Diffuse Large B Cell Lymphoma

Edwin Wei Sheng Thong, Andrew Makmur, Yen-Lin Chee, James Hallihan, Lenith Tai Jit Cheng, Nesaretnam Barr Kumarakulasinghe, Anand Devaprasath Jeyasekharan, Joanne Shu Xian Lee, Sanjay De Mel, Esther Hian Li Chan, Michelle Poon, Wee-Joo Chng, Jayalakshmi ., Melati Dewi Ali, Wei-Ying Jen, Desmond Shi Wei Lim

Blood (2023) 142 (Supplement 1): 3652.

https://doi.org/10.1182/blood-2023-178239

Published: 2023

NARROW

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1- mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Integrating Genomics and Functional Phenotypes to Refine Risk Assessment in Acute Myeloid Leukemia across the Age Spectrum: Insights from Singapore

Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Impact of Flow Cytometry-Based Measurable Residual Disease Clearance Kinetics in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Characteristics and Outcomes of Acute Myeloid Leukemia in Ethnically Diverse Asians in Singapore

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

A Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Relapsed and / or Refractory Myeloma: A Report from the Asian Myeloma Network

Clinical Evaluation of a Functional Combinatorial Precision Medicine Platform to Predict Patient-Specific Treatment Outcomes in Acute Myeloid Leukemia

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Survival Outcomes, Efficacy and Tolerability of a Pediatric-Inspired Regimen (MASPORE) for Philadelphia-Negative Acute Lymphoblastic Leukemia in Young Adults at a Tertiary Hospital in Singapore

Randomized Phase 3 Study of Pomalidomide Cyclophosphamide Dexamethasone (PCD) Versus Pomalidomide Dexamethasone (PD) in Relapse or Refractory Myeloma: An Asian Myeloma Network (AMN) Study

Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Mitochondrial Functional Profiling Links Apoptotic Sensitivity to Treatment Outcomes Based on Age and Cell Lineage in Acute Leukemia

Development of a Novel Artificial Intelligence Tool to Measure Psoas Volumes in Patients with Diffuse Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only